Liver Diseases  >>  pioglitazone  >>  Phase 4
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pioglitazone / Generic mfg.
NCT00227110: Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

Completed
4
55
US
Pioglitazone, Actos (Takeda Pharmaceuticals)., Placebo
The University of Texas Health Science Center at San Antonio, National Institutes of Health (NIH), Takeda Pharmaceuticals North America, Inc.
Nonalcoholic Steatohepatitis
11/05
01/06
NCT00570622: Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis

Completed
4
20
Europe
Pioglitazone, Placebo
Medical University of Vienna
Cirrhosis, Ascites, Portal Hypertension
11/08
11/08
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Completed
4
155
US
peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos
Hoffmann-La Roche
Hepatitis C, Chronic
12/10
12/10
NCT00926614: Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

Completed
4
20
US
pioglitazone (Actos), Actos, atorvastatin (Lipitor), Lipitor
Brooke Army Medical Center
Hepatitis c
06/11
12/11
NCT00742326: Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

Terminated
4
13
US
Pioglitazone, Avandia, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
01/13
01/13
UTHSCSA NASH , NCT00994682: University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (Trial)

Completed
4
176
US
Pioglitazone study drug, Actos (brand name), manufactured by Takeda Pharmaceuticals., Placebo, Pioglitazone Open Label
University of Florida, The University of Texas at San Antonio
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
12/14
12/14
VA NASH, NCT01002547: Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

Completed
4
105
US
pioglitazone-placebo, pioglitazone, Actos, Vitamin E, Vitamin E-placebo
VA Office of Research and Development
Nonalcoholic Steatohepatitis
09/16
12/16

Download Options